Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies

Abstract

AimsLittle is known about the frequency with which suspected adverse drug reactions are seen by general practitioners after the prescription of newly marketed drugs. We investigated age and sex specific incidence rates of suspected adverse drug reactions recorded by general practitioners in England after the prescription of selected newly marketed drugs. Methods Information was collected from 48 national cohort studies of newly marketed drugs studied by prescription-event monitoring. Questionnaires were sent to prescribers asking for details of events and suspected adverse drug reactions recorded in the patients' notes occurring after the drugs were prescribed. Results During the 48 cohort studies, a total of 513 608 patients were investigated, of which 221 781 (43.2%) were males and 285 862 (55.7%) were females. The overall incidence of suspected adverse drug reactions in males was 12.9 per 10 000 patientmonths of exposure (95% confidence limits 12.3 to 13.5), and in females was 20.6 per 10 000 patient-months of exposure (95% confidence limits 19.9 to 21.3). The overall age-standardised relative risk of an adverse drug reaction in females compared with males was 1.6 (1.5-1.7). This sex difference was significant in all age groups above 19 years of age, and was relatively consistent across all age groups (x 2 test for heterogeneity= 9.2, P=0.3). The highest rate of recording in males was in the 50-59 year age group, and in females was in the 30-39 year age group. Conclusions In general practice in England, suspected adverse drug reactions to newly marketed drugs are recorded more often in adults aged between 30 and 59 years of age and are 60% more common in women than in men. The sex difference occurs in all age groups over 19 years of age.

Reacciones adversas a medicamentos en pacientes que acudieron a un hospital general: un meta-análisis de resultados

“…La bibliografía muestra un porcentaje mayor de mujeres con RAM frente a los varones, sobre todo para ciertos fármacos tales como: digoxina, AINE, antisicóticos antihistamínicos, gastrocinéticos, antiarrítmicos y analgésicos por causas aún no bien conocidas (17)(18)(19)(20). En este sentido nuestros resultados confirman los de una amplia revisión sobre el tema en la que se concluye que el género femenino es un factor controvertido con la presencia de RAM aún no resuelto (21).…”

Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil

“…Epidemiologic studies in large population samples have shown an increased risk of adverse drug effects among females 31,32 however, most MDA dosages in LF elimination programs have been defined based on population parameters of weight-for-age 13,14,33,34 and have not considered sex variations in weight in terms of the tolerability of antifilarial drugs. The data from this study suggest that adjusting dosage schedules in MDA by genders may reduce the occurrence of ADRs, primarily by reducing the number of ADRs in the female population.…”

Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers

“…Several studies have reported the influence of sex on ADRs (51,52,53). These differences might be related with differences in the exposure of women and men to drugs (53,54).…”